Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05475834
Other study ID # SIM0417-104
Secondary ID
Status Completed
Phase Phase 1
First received
Last updated
Start date July 21, 2022
Est. completion date August 7, 2022

Study information

Verified date September 2022
Source Jiangsu Simcere Pharmaceutical Co., Ltd.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a non-randomized, open-label, single-dose, Phase I clinical study to evaluate the mass balance and biotransformation, safety and tolerability of SIM0417 in healthy Chinese adult male subjects following a single oral administration of SIM0417 in combination with ritonavir.


Description:

This is a single-center, non-randomized, open-label, single-cohort, single-dose, Phase I clinical study to evaluate the mass balance, biotransformation, safety, and tolerability of SIM0417 following a single oral administration of SIM0417 combination with ritonavir in healthy Chinese adult male subjects. This study is planned to enroll 6-8 healthy male subjects, each subject will receive SIM0417 combined with ritonavir administration. SIM0417 is single dosed, and ritonavir is administered 12 hours before SIM0417 administration (-12h), at the time of SIM0417 administration (0h), 12h (12h), and 24h (24h) after SIM0417 administration. SIM0417 is administered after meals, ritonavir is administered either in fasting condition or after meals.


Recruitment information / eligibility

Status Completed
Enrollment 6
Est. completion date August 7, 2022
Est. primary completion date August 7, 2022
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Male
Age group 18 Years to 55 Years
Eligibility Inclusion Criteria: 1. Fully understand the research content, process, and potential risks of this trial, voluntarily participate in the clinical trial and sign the informed consent. 2. Healthy male subjects aged =18 years and =55 years old. 3. Body weight =50 kg, body mass index =19 kg/m2 and =28 kg/m2. 4. Subjects agree to take recognized effective contraceptive measures during the study period and within 3 months after the last dose of the study drug, starting from signing the informed consent. Exclusion Criteria: 1. Any diseases that may affect the study results or the safety and status of the subjects, including but not limited to the central nervous system, respiratory system, cardiovascular system, alimentary system, blood and lymphatic system, endocrine system, musculoskeletal system, hepatic and kidney function obstacle. 2. Difficulty in venous blood collection, a history of fainting blood or needles, or those who cannot tolerate blood collection with intravenous indwelling needles. 3. With dysphagia or any history of gastrointestinal diseases that affect drug absorption/metabolism/excretion (including habitual constipation or diarrhea, perianal disease or hematochezia, irritable bowel syndrome, inflammatory bowel disease, etc.). 4. Have special requirements for diet and cannot comply with the provided diet and corresponding regulations. 5. With specific allergic history ( asthma, urticaria, eczema, etc. ) or allergic constitution ( such as those allergic to two or more drugs, food such as milk, and pollen ) are allergic to any component of the research drug or research drug. 6. Have taken special diet ( including of pitaya, mango, grapefruit, food or beverage containing caffeine, etc. ) or intense exercise within 48 h before the first administration of the drug. 7. Any prescription, non-prescription, vitamin, or herbal medicine was taken within 4 weeks before and during the screening period. 8. During the first 3 months prior to screening or from the screening period to the first administration period, alcohol was often consumed, i.e., more than 2 units of alcohol per day ( 1 unit = 360 mL beer or 45 mL spirits with 40 % alcohol or 150 mL wine ); or alcohol breath test positive. 9. More than 5 cigarettes per day during the 3 months prior to screening. 10. Participated in any drug clinical trial as a subject within 3 months prior to screening and took the study drug. 11. With blood donation or blood loss was greater than 200 mL within 3 months prior to screening, or blood transfusion or blood products were received within 4 weeks. 12. Have a history of drug abuse or be positive in drug abuse screening test. 13. At the time of screening, the blood pressure in the resting state and the pulse are within the following ranges: such as systolic blood pressure <90 mmHg or =140 mmHg, diastolic blood pressure <60 mmHg or =90 mmHg, pulse <55 bpm or >100 bpm. 14. Electrocardiographic QTc > 450 msec (Fridericia formula) at screening, or presence of risk factors for Torsade de Pointes (eg, history of heart failure, history of hypokalemia, family with prolonged QT syndrome) history), or other abnormal clinical significance (judged by the investigator). 15. HBV surface antigen, HCV antibody, HIV, or syphilis are positive during screening. 16. Physical examination, vital signs, blood routine, blood biochemistry ( serum creatinine > 1.0 × ULN )), coagulation function, thyroid function, urine examination, chest X-ray, abdominal B-scan ultrasonography, thyroid B-scan ultrasonography results were abnormal and have clinical significance (judged by the investigator). 17. Those who have been vaccinated within 1 month before screening (except for the novel coronavirus vaccine), or who plan to be vaccinated during treatment / within 2 weeks after the last dose of study drug. 18. Be positive in SARS-CoV-2 nucleic acid test at screening. 19. Subjects have other conditions that are not suitable for participating in this research, or the subjects may not be able to complete this research for other reasons (judged by the investigator).

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
SIM0417
Single oral dose of 750 mg SIM0417 coadministered with 100 mg ritonavir.

Locations

Country Name City State
China Shandong First Medical University Jinan Shandong

Sponsors (1)

Lead Sponsor Collaborator
Jiangsu Simcere Pharmaceutical Co., Ltd.

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Total recovery of SIM0417-related substances in urine Total recovery of SIM0417-related substances in urine after a single dose of SIM0417 in combination with ritonavir, elucidating the main route of excretion, and clarifying the cumulative recovery of the parent drug and its metabolites (if applicable) Up to 168 hours(approx) from SIM0417 administration
Primary Total recovery of SIM0417-related substances in feces Total recovery of SIM0417-related substances in feces after a single dose of SIM0417 in combination with ritonavir, elucidating the main route of excretion, and clarifying the cumulative recovery of the parent drug and its metabolites (if applicable) Up to 168 hours(approx) from SIM0417 administration
Primary Identification of metabolites in plasma Identification of metabolites in plasma (if applicable), to identification of major biotransformation pathways Up to 72 hours (approx) from SIM0417 administration
Primary Identification of metabolites in urine Identification of metabolites in urine (if applicable), to identification of major biotransformation pathways Up to 168 hours (approx) from SIM0417 administration
Primary Identification of metabolites in feces Identification of metabolites in feces (if applicable), to identification of major biotransformation pathways Up to 168 hours (approx) from SIM0417 administration
Secondary Adverse Events Number of Participants With Adverse Events Up to 14 days from SIM0417 administration
Secondary Vital Signs Number of Participants With Clinically Notable Vital Signs Up to 8 days from SIM0417 administration
Secondary ECG Number of Participants With Clinically Notable Electrocardiogram (ECG) Values Up to 8 days from SIM0417 administration
Secondary Laboratory Tests Number of Participants With Clinically Notable Laboratory Tests Up to 8 days from SIM0417 administration
See also
  Status Clinical Trial Phase
Completed NCT05523687 - AME Study of [14C]-PC14586 in Healthy Male Participants Phase 1
Completed NCT02250976 - The Pharmacokinetic Study of the Fixed-dose Combination of Micronized Fenofibrate and Pitavastatin Ca Phase 1
Completed NCT01948011 - Racecadotril Suspension Linearity Study & Comparative Bioavailability Versus Granules Phase 1
Completed NCT04086719 - An Investigational Study to Determine the Drug Level Profile of BMS-986165 in Healthy Male Volunteers Following Transporter Inhibition. Phase 1
Completed NCT03686501 - D1 Receptor Occupancy (RO) Following a Single Dose of PF-06412562 Early Phase 1
Terminated NCT01965301 - First-time-in-man, to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BP1.5375 Phase 1
Completed NCT01005160 - Drug Interaction Between CKD-501 and Metformin Phase 1
Completed NCT04534582 - Pharmacokinetic, Safety and Immunogenicity Phase I Study of HLX14 Versus Prolia® in Healthy Male Subjects Phase 1
Recruiting NCT06159101 - A Study to Compare the PK , Safety, Tolerability, and Immunogenicity of HLX13 With YERVOY in Male Subjects Phase 1
Completed NCT01549743 - The Pharmacokinetic Interaction Between Celecoxib and Rebamipide Phase 1
Completed NCT03532854 - Evaluating a Pharmacokinetic Drug Interaction Between LGEV1801 and LGEV1802 Phase 1
Recruiting NCT03530228 - A Phase 1 Study of Tegoprazan on Healthy Male Volunteers Phase 1
Completed NCT01356043 - CKD-828 Drug Interaction Study (S-amlodipine) Phase 1
Completed NCT04810533 - The Absorption, Metabolism and Excretion of [14C]SH-1028 in Chinese Healthy Male Volunteers Phase 1
Completed NCT03089112 - Pharmacokinetic Drug Interactions Between HGP1607 and HGP1501 Phase 1
Completed NCT01939639 - The Influence of Oxytocin on the Processing of Social Contact Phase 1
Completed NCT01342055 - Pharmacokinetics and Safety Study of Apetrol ES in Healthy Male Volunteers Phase 1
Terminated NCT03863587 - Compare Pharmacokinetic, Safety, Tolerability and Immunogenicity of HLX12 and Ramucirumab in Healthy Male Adult Subjects Phase 1
Completed NCT01382017 - Effects of Lacosamide on Human Motor Cortex Excitability: a Transcranial Magnetic Stimulation Study N/A
Completed NCT01356017 - CKD-828 Drug Interaction Study (Telmisartan) Phase 1